Integrating Lenses — What Premortem and Bird's-Eye View Add to Material Review

When reviewing promotional materials, asking only "does this wording satisfy the rule?" leaves a category of problems invisible. The impression a document delivers to a physician. The risks a patient faces after the prescription is written. The basis of judgment that gets scrutinized when something surfaces later — none of these can be caught without a different kind of attention than rule-by-rule compliance. Switching perspectives. Holding more than one at once. Then integrating them into a single judgment. That metacognitive skill is the subject of this piece.

So What / So Why — The Core of This Lens

The regulatory eye asks: "Does this slide contain any rule violations?" The patient's eye asks: "What happens to me if I take this drug?" The integrative lens covered here looks at both from one level up. "Where could this material fail?" (premortem) and "What does this material communicate as a whole?" (bird's-eye view) — these two are the pillars.

Premortem originates in project management. Before a project is approved, you ask: "Assume this project has already failed — what caused it?" Pulled into material review, the question becomes: "Assume this material becomes a problem six months from now — where is the weak point?" Individual items may all pass, but if this question stops you cold, something is missing.

Bird's-eye view is seeing the forest from above rather than one tree at a time. The question is not "Is this slide accurate?" but "What will the physician believe after reading the final slide?" Cherry-picking and the underplaying of safety data become problems not within individual slides, but in the overall impression the document delivers. Most of the deviations that Japan's Ministry of Health, Labour and Welfare (MHLW) monitoring reports documented over seven years slipped past individual rule checks while painting a distorted picture in aggregate.

Why does review need this? Because checking statements and reading impressions are different tasks. Even after confirming regulatory compliance slide by slide, you go back and read the finished document as a continuous stream of information. Without that end-to-end pass, precision in the parts can hide distortion in the whole. The short answer to "So why": only this integrative lens stops deviations that individual checks have already cleared.

Inside the Lens — What, Where, Why, How

What (what does this lens look at?)
The premortem lens looks at failure scenarios. Ask "If this material becomes a problem in a year, what caused it?" and write down three candidates. Subgroup results presented without the full-population analysis. Overseas trial results shown alone while a non-significant domestic trial goes unmentioned. An adverse-event table with the threshold quietly raised. These are findable if you ask in advance; they rarely surface through rule-checklist review alone. The bird's-eye lens looks at the receiver's impression. Does the ratio of efficacy graphics to safety information reflect what the trial actually showed? Are primary endpoints more prominent than secondary ones? Try writing in one sentence what a physician believes after finishing the document.

Where (when in the process?)
Premortem is most effective just before final approval — after the deck is complete and the review team has signed off. Stop once and ask: "Can I name three failure scenarios before this goes out?" Bird's-eye view belongs in the end-to-end pass: after slide-by-slide review is done, read straight through from the first slide to the last, taking about fifteen minutes. Both sit between part-by-part review and final sign-off.

Why (why does this moment need this lens?)
Material production is divided labor. The person who draws the graph, the person who builds the slide, the person who writes the copy, and the person who checks regulatory compliance are all different. Each can do their part accurately, yet if no one looks at the whole, deviations pass through. Beyond that, the relief of "we're good" is real — and it intensifies as deadlines approach. Premortem and bird's-eye view build in a pause: suspend that relief and ask what is missing.

How (in practice)?
Premortem is simple. Before approval, take a blank sheet and spend three minutes writing three reasons why this material could become a problem. If nothing comes, the question may be too shallow. For bird's-eye view: after closing the final slide, write one sentence — "What will a physician change about their prescribing after seeing this document?" If that sentence diverges from what the trial actually showed, something has bent.

Getting Inside the Perspective — Inhabiting the Role

To enter the premortem perspective, I imagine a regulatory reviewer who has just received an adverse event report. A patient has filed a complaint, and this person is picking up the material for the first time. They read from page one. On which page are the primary endpoint results from the trial? Where is the complete adverse event list? Is there a comparison of domestic and overseas trial data? Does the adverse event threshold match the original publication? Standing in the position of someone searching for these things makes the material's gaps visible. "Not written" is not the same as "no problem." Finding what is not written is the reviewer's job.

To enter the bird's-eye perspective, I step briefly into the role of the physician receiving the information — not a specialist, but a busy general internist. Several medical representatives visit each week, and each material gets five to ten minutes. The efficacy graph is large; the comparator arm is absent; safety data occupies the last two slides. What does this physician believe? They will carry an impression that the drug works. But from this material they have no basis for "which patients should not receive it" or "how does the adverse event rate compare to other agents?" The prescription begins from that state.

This is not dramatization or the construction of imaginary adversaries. Many of the cases recorded in the MHLW monitoring reports had a structure where the problem was visible on first reading — if you were looking from either of these two positions. Premortem is the eye of "the reviewer who arrives after the failure"; bird's-eye view is the eye of "the physician who received the material." Switching between these two deliberately while reading a document is what integrative-lens practice looks like.

Past Deviations as a Mirror — Re-reading Cases Through These Lenses

Two real cases, re-read through premortem and bird's-eye view.

Case 1: Asthma Subgroup Selection, Viewed Through Premortem (FY2018)

Case 2: Systemic Information Selection for a Heart Failure Drug, Viewed Through Bird's-Eye View (FY2022)